Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;48(11):3702-3711.
doi: 10.1007/s00259-021-05355-7. Epub 2021 Apr 12.

Detection of clinically significant prostate cancer with 18F-DCFPyL PET/multiparametric MR

Ur Metser  1 , Claudia Ortega  2 , Nathan Perlis  3 , Eli Lechtman  2 , Alejandro Berlin  4 , Reut Anconina  2 , Yael Eshet  2 , Rosanna Chan  2 , Patrick Veit-Haibach  2 , Theodorus H van der Kwast  5 , Amy Liu  6 , Sangeet Ghai  2
Affiliations

Detection of clinically significant prostate cancer with 18F-DCFPyL PET/multiparametric MR

Ur Metser et al. Eur J Nucl Med Mol Imaging. 2021 Oct.

Abstract

Purpose: To assess whether 18F-DCFPyL PET/multiparametric (mp)MR contributes to the diagnosis of clinically significant (cs) prostate cancer (PCa) compared to mpMR in patients with suspicion of PCa, or patients being considered for focal ablative therapies (FT).

Patients and methods: This ethics review board-approved, prospective study included 55 men with suspicion of PCa and negative systematic biopsies or clinically discordant low-risk PCa (n = 21) or those being considered for FT (n = 34) who received 18F-DCFPyL PET/mpMR. Each modality, PET, mpMR, and PET/MR (using the PROMISE classification), was assessed independently. All suspicious lesions underwent PET/MR-ultrasound fusion biopsies.

Results: There were 45/55 patients (81.8%) that had histologically proven PCa and 41/55 (74.5%) were diagnosed with csPCa. Overall, 61/114 lesions (53.5%) identified on any modality were malignant; 49/61 lesions (80.3%) were csPCa. On lesion-level analysis, for detection of csPCa, the sensitivity of PET was higher than that of mpMR and PET/MR (86% vs 67% and 69% [p = 0.027 and 0.041, respectively]), but at a lower specificity (32% vs 85% and 86%, respectively [p < 0.001]). The performance of MR and PET/MR was comparable. For identification of csPCa in PI-RADS ≥ 3 lesions, the AUC (95% CI) for PET, mpMR, and PET/MR was 0.75 (0.65-0.86), 0.69 (0.56-0.82), and 0.78 (0.67-0.89), respectively. The AUC for PET/MR was significantly larger than that of mpMR (p = 0.04).

Conclusion: PSMA PET detects more csPCa than mpMR, but at low specificity. The performance PET/MR is better than mpMR for detection of csPCa in PI-RADS ≥ 3 lesions.

Clinical registration: NCT03149861.

Keywords: 18F-DCFPyL; Multiparametric MR; PET/MR; PSMA; Prostate cancer.

PubMed Disclaimer

References

    1. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol. 2002;167:2435–9. - DOI
    1. Kvåle R, Møller B, Wahlqvist R, Fosså SD, Berner A, Busch C, et al. Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study. BJU Int. 2009;103:1647–54. - DOI
    1. Tosoian JJ, Sundi D, Trock BJ, Landis P, Epstein JI, Schaeffer EM, et al. Pathologic outcomes in favorable-risk prostate cancer: comparative analysis of men electing active surveillance and immediate surgery. Eur Urol. 2016;69(4):576–81. - DOI
    1. Vourganti S, Rastinehad A, Yerram NK, Nix J, Volkin D, Hoang A, et al. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J Urol. 2012;188(6):2152–7. - DOI
    1. Cornelis F, Rigou G, Le Bras Y, Coutouly X, Hubrecht R, Yacoub M, et al. Real-time contrast-enhanced transrectal US-guided prostate biopsy: diagnostic accuracy in men with previously negative biopsy results and positive MR imaging findings. Radiology. 2013;269(1):159–66. - DOI

Associated data

LinkOut - more resources